Research Article

Comprehensive analysis of multiple parameters associated with tumor immune microenvironment in ARID1A mutant cancers

Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250117, PR China

Search for more papers by this author

Jiamao Lin

Department of Medical Oncology, Shandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250117, PR China

Search for more papers by this author

Lijuan Zhang

Department of Pediatric Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, PR China

Search for more papers by this author

Jingchao Li

Department of Radiation Oncology, The People’s Hospital of Zhangqiu Area, Jinan 250200, China

Search for more papers by this author

Yingyun Zhang

Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250117, PR China

Search for more papers by this author

Chenglong Zhao

*Author for correspondence: Tel.: +86 0531 676 26332;

E-mail Address: zcl.125@163.com

Department of pathology, Shandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250117, PR China

Search for more papers by this author

Haiyong Wang

**Author for correspondence: Tel.: +86 0531 6762 6332;

E-mail Address: wanghaiyong6688@126.com

https://orcid.org/0000-0003-0072-3949

Department of Medical Oncology, Shandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250117, PR China

Search for more papers by this author

Published Online:8 Jul 2020https://doi.org/10.2217/fon-2020-0243

View article

Abstract

Aim: To verify the relationship between ARID1A and tumor immune microenvironment thus immune checkpoint inhibitors (ICIs) response. Material & methods: Several public databases were used to characterize the association between ARID1A gene alteration and tumor immunity. Results: The gene mutation frequency was 8.2% in all cancer types. The ARID1A-mutated cancers have higher scores of mutation count, tumor mutational burden, neoantigen load (p < 0.001) and T cell repertoire, B cell repertoire diversity (p < 0.05). The gene mutation has tight association with multiple-activated immune cells. Survival analysis suggested that patients with ARID1A mutant cancers benefit more from ICIs treatment (p = 0.013). Conclusion: The ARID1A gene mutation was correlated with higher tumor immunogenicity and activated antitumor immune microenvironment, resulting in superior cohort that respond well to ICIs.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Callahan MK, Postow MA, Wolchok JD. Targeting T cell co-receptors for cancer therapy. Immunity 44(5), 1069–1078 (2016).Crossref, Medline, CAS, Google Scholar
2. Keenan TE, Burke KP, Van Allen EM. Genomic correlates of response to immune checkpoint blockade. Nat. Med. 25(3), 389–402 (2019).Crossref, Medline, CAS, Google Scholar
3. Ren D, Hua Y, Yu B et al. Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. Mol. Cancer 19(1), 19 (2020).Crossref, Medline, Google Scholar
4. Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 17(12), e542–e551 (2016).Crossref, Medline, CAS, Google Scholar
5. Aguiar PN Jr, Santoro IL, Tadokoro H et al. The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. Immunotherapy 8(4), 479–488 (2016).Link, CAS, Google Scholar
6. Signorelli D, Giannatempo P, Grazia G et al. Patients selection for immunotherapy in solid tumors: overcome the naive vision of a single biomarker. Biomed. Res. Int. 2019, 9056417 (2019).Crossref, Medline, Google Scholar
7. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1), 1–10 (2013).Crossref, Medline, Google Scholar
8. Colli LM, Machiela MJ, Zhang H et al. Landscape of combination immunotherapy and targeted therapy to improve cancer management. Cancer Res. 77(13), 3666–3671 (2017). • Reviews the current predictive factors for treatment of immune checkpoint inhibitors treatment.Crossref, Medline, CAS, Google Scholar
9. Tu MM, Lee FYF, Jones RT et al. Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy. Sci. Adv. 5(2), eaav2437 (2019).Crossref, Medline, CAS, Google Scholar
10. Toumpeki C, Liberis A, Tsirkas I et al. The role of ARID1A in endometrial cancer and the molecular pathways associated with pathogenesis and cancer progression. In Vivo 33(3), 659–667 (2019).Crossref, Medline, CAS, Google Scholar
11. Fukumoto T, Magno E, Zhang R. SWI/SFN complexes in ovarian cancer: mechanistic insights and therapeutic implications. Mol. Cancer Res. 16(12), 1819–1825 (2018).Crossref, Medline, CAS, Google Scholar
12. Mathur R. ARID1A loss in cancer: towards a mechanistic understanding. Pharmacol. Ther. 190, 15–23 (2018).Crossref, Medline, CAS, Google Scholar
13. Shen J, Ju Z, Zhao W et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat. Med. 24(5), 556–562 (2018).Crossref, Medline, CAS, Google Scholar
14. Li L, Li M, Jiang Z, Wang X. ARID1A mutations are associated with increased immune activity in gastrointestinal Cancer. Cells 8(7), pii: E678 (2019).Crossref, Google Scholar
15. Li J, Wang W, Zhang Y et al. Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. J. Clin. Invest. pii: 134402 (2020). • Summarizes about ARID1A alteration and function in cancer development and tumor immunity.Google Scholar
16. Li T, Fan J, Wang B et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 77(21), e108–e110 (2017).Crossref, Medline, CAS, Google Scholar
17. Cerami E, Gao J, Dogrusoz U et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2(5), 401–404 (2012).Crossref, Medline, Google Scholar
18. Zehir A, Benayed R, Shah RHet al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10000 patients. Nat Med. 23(6), 703–713(2017).Crossref, Medline, CAS, Google Scholar
19. Cheng DT, Mitchell TN, Zehir A et al. Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J. Mol. Diagn. 17(3), 251–264 (2015).Crossref, Medline, CAS, Google Scholar
20. Samstein RM, Lee CH, Shoushtari AN et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51(2), 202–206 (2019).Crossref, Medline, CAS, Google Scholar
21. Thorsson V, Gibbs DL, Brown SD et al. The immune landscape of cancer. Immunity 48(4), 812–830 (2018).Crossref, Medline, CAS, Google Scholar
22. Saltz J, Gupta R, Hou L et al. Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images. Cell Rep. 23(1), 181–193 (2018). • Introduces several online public database used in this study.Crossref, Medline, CAS, Google Scholar
23. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 348(6230), 56–61 (2015).Crossref, Medline, CAS, Google Scholar
24. Galon J, Bruni D. Tumor immunology and tumor evolution: intertwined histories. Immunity 52(1), 55–81 (2020).Crossref, Medline, CAS, Google Scholar
25. Fridman WH Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12(4), 298–306 (2012).Crossref, Medline, CAS, Google Scholar
26. Horton BL, Fessenden TB, Spranger S. Tissue site and the cancer immunity cycle. Trends Cancer 5(10), 593–603 (2019).Crossref, Medline, CAS, Google Scholar
27. Liu C, Zheng S, Jin R et al. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer Lett. 470, 95–105 (2020).Crossref, Medline, CAS, Google Scholar
28. Lhuillier C, Rudqvist NP, Elemento O, Formenti SC, Demaria S. Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system. Genome Med. 11(1), 40 (2019).Crossref, Medline, Google Scholar
29. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160(1–2), 48–61 (2015). •• The complexity and diversity of tumor immune microenvironment makes it difficult to explore powerful predictors for immunotherapy. It is urgent to find a new direction on predictor exploration for immunotherapy response.Crossref, Medline, CAS, Google Scholar
30. Golubovskaya V, Wu L. Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy. Cancers 8(3), 1–12 (2016).Crossref, Google Scholar
31. Murphy KA, Bhamidipati K, Rubin SJS, Kipp L, Robinson WH, Lanz TV. Immunomodulatory receptors are differentially expressed in B and T cell subsets relevant to autoimmune disease. Clin. Immunol. 209, 108276 (2019).Crossref, Medline, CAS, Google Scholar
32. Eivazi S, Bagheri S, Hashemzade MS et al. Development of T follicular helper cells and their role in disease and immune system. Biomed. Pharmacother. 84, 1668–1678 (2017).Crossref, Google Scholar
33. Asadzadeh Z, Mohammadi H, Safarzadeh E et al. The paradox of Th17 cell functions in tumor immunity. Cell. Immunol. 322, 15–25 (2017).Crossref, Medline, CAS, Google Scholar
34. Stockis J, Roychoudhuri R, Halim TYF. Regulation of regulatory T cells in cancer. Immunology 157(3), 219–231 (2019).Crossref, Medline, CAS, Google Scholar
35. Hollern DP, Xu N, Thennavan A et al. B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer. Cell 179(5), 1191–1206 (2019). • Various subtypes of T and B cells existed in tumor immune microenvironment exhbits complex and different function in cancer immunity.Crossref, Medline, CAS, Google Scholar
36. Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat. Rev. Drug Discov. 19, 200–218 (2020).Crossref, Medline, CAS, Google Scholar
37. Den Brok MH, Nierkens S, Figdor CG, Ruers TJ, Adema GJ. Dendritic cells: tools and targets for antitumor vaccination. Expert Rev. Vaccines 4(5), 699–710 (2005).Crossref, Medline, Google Scholar
38. Jeong J, Suh Y, Jung K. Context drives diversification of monocytes and neutrophils in orchestrating the tumor microenvironment. Front. Immunol. 10, 1817 (2019).Crossref, Medline, CAS, Google Scholar
39. Tamura R, Tanaka T, Yamamoto Y, Akasaki Y, Sasaki H. Dual role of macrophage in tumor immunity. Immunotherapy 10(10), 899–909 (2018).Link, CAS, Google Scholar
40. Varricchi G, Galdiero MR, Loffredo S et al. Are mast cells MASTers in cancer? Front. Immunol. 8, 424 (2017).Crossref, Medline, Google Scholar
41. Wouters MCA, Nelson BHP. Prognostic significance of tumor-infiltrating B cells and plasma cells in human cancer. Clin. Cancer Res. 24(24), 6125–6135 (2018). • Complex and diverse roles of other subtypes of immune cells including NK cells, monocytes, macrophage and plasma cells in tumor immunity.Crossref, Medline, CAS, Google Scholar
42. Tang H, Wang Y, Chlewicki LK et al. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell 29(3), 285–296 (2016).Crossref, Medline, CAS, Google Scholar

Vol. 16, No. 29

Metrics

Downloaded 129 times

History

Received 20 March 2020

Accepted 22 June 2020

Published online 8 July 2020

Published in print October 2020

Information

Keywords

Financial & competing interests disclosure

This study was supported jointly by the national natural science foundation of China (grant no. 81602031), special funds for Taishan Scholars Project (grant no. tsqn201812149) and Academic Promotion Programme of Shandong First Medical University (2019RC004). All authors have contributed significantly to the content of the article, have read and approve the submission of the manuscript. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download